These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33363383)

  • 21. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
    Yoshimura A; Takeda T; Kataoka N; Tanimura K; Fukui M; Chihara Y; Takei S; Kawachi H; Nakanishi K; Yamanaka Y; Tamiya N; Honda R; Okura N; Yamada T; Uryu K; Murai J; Shiotsu S; Yoshioka H; Yamada T; Kurata T; Takayama K
    Front Oncol; 2024; 14():1303543. PubMed ID: 38344209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.
    Zhang P; Ma M; Nie J; Dai L; Hu W; Zhang J; Wu D; Chen X; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Hao Q; Fang J
    Heliyon; 2024 Feb; 10(4):e26026. PubMed ID: 38390071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Guo T; Chu L; Chu X; Yang X; Li Y; Zhou Y; Xu D; Zhang J; Wang S; Hu J; Chu Q; Moran T; Cho WC; Merrell KW; Rizzo S; Liu Y; Ni J; Zhu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):173-187. PubMed ID: 35280308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
    Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
    J Neurosurg; 2020 Sep; 133(3):685-692. PubMed ID: 31349225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death 1 inhibitors with or without concurrent brain radiotherapy for lung cancer patients with brain metastases.
    Huang Y; Li H; Peng L; Tong F; Wen L; Zhang R; Cheng S; Dong X
    Ann Palliat Med; 2021 Sep; 10(9):9974-9983. PubMed ID: 34628921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
    Ge W; Wu N; Jalbert JJ; Quek RGW; Liu J; Rietschel P; Pouliot JF; Harnett J; Hsu ML; Feliciano JL
    Cancer Manag Res; 2022; 14():3191-3202. PubMed ID: 36415537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
    Zhang F; Huang D; Zhao L; Li T; Zhang S; Zhang G; Yuan F; Zhang J; Zhang Y; Zhao Z; Cui L; Zhao J; Wang G; Cai S; Bai Y; Wang J; Hu Y
    Ther Adv Med Oncol; 2020; 12():1758835920936882. PubMed ID: 32670420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy.
    Zhao S; Jiang W; Yang N; Liu L; Yu Y; Wang Q; Zhao Y; Yang Y; Ma S; Yu Q; Zhang L; Huang Y
    Transl Lung Cancer Res; 2024 Feb; 13(2):269-279. PubMed ID: 38496686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis.
    Wu M; Jiang J; Zhang X; Chen J; Chang Q; Chen R
    Front Oncol; 2022; 12():1024833. PubMed ID: 36518310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
    Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
    Qiao M; Zhou F; Hou L; Li X; Zhao C; Jiang T; Gao G; Su C; Wu C; Ren S; Zhou C
    Ann Transl Med; 2021 Jan; 9(1):34. PubMed ID: 33553327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
    Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
    Front Oncol; 2020; 10():572853. PubMed ID: 33163403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in the prescription of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis.
    Suazo-Zepeda E; Maas WJ; Vinke PC; Hiltermann TJN; Aarts MJ; de Bock GH; Heuvelmans MA
    Transl Lung Cancer Res; 2024 Sep; 13(9):2202-2211. PubMed ID: 39430329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
    Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
    Front Oncol; 2022; 12():974227. PubMed ID: 36523994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.